References
- Barnes JW, Tischkau SA, Barnes JA, Mitchell JW, Burgoon PW, Hickok JR, Gillette MU. 2003. Requirement of mammalian Timeless for circadian rhythmicity. Science. 302(5644):439–42. doi:10.1126/science.1086593. PMID: 14564007.
- Bass J. 2012. Circadian topology of metabolism. Nature. 491(7424):348–56. doi:10.1038/nature11704. PMID: 23151577.
- Bhatti P, Cushing-Haugen KL, Wicklund KG, Doherty JA, Rossing MA. 2013. Nightshift work and risk of ovarian cancer. Occup Environ Med. 70(4):231–37. doi:10.1136/oemed-2012-101146. PMID: 23343856.
- Cadenas C, Van De Sandt L, Edlund K, Lohr M, Hellwig B, Marchan R, Schmidt M, Rahnenfuhrer J, Oster H, Hengstler JG. 2014. Loss of circadian clock gene expression is associated with tumor progression in breast cancer. Cell Cycle. 13(20):3282–91. doi:10.4161/15384101.2014.954454. PMID: 25485508.
- Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. 2014. Non-small-cell lung cancers: A heterogeneous set of diseases. Nat Rev Cancer. 14(8):535–46. doi:10.1038/nrc3775. PMID: 25056707.
- Elgohary N, Pellegrino R, Neumann O, Elzawahry HM, Saber MM, Zeeneldin AA, Geffers R, Ehemann V, Schemmer P, Schirmacher P, others. 2015. Protumorigenic role of Timeless in hepatocellular carcinoma. Int J Oncol. 46(2):597–606. doi:10.3892/ijo.2014.2751. PMID: 25405317.
- Fahrenkrug J, Georg B, Hannibal J, Hindersson P, Gras S. 2006. Diurnal rhythmicity of the clock genes Per1 and Per2 in the rat ovary. Endocrinology. 147(8):3769–76. doi:10.1210/en.2006-0305. PMID: 16675517.
- Gauger MA, Sancar A. 2005. Cryptochrome, circadian cycle, cell cycle checkpoints, and cancer. Cancer Res. 65(15):6828–34. doi:10.1158/0008-5472.CAN-05-1119. PMID: 16061665.
- Gerard C, Goldbeter A. 2012. Entrainment of the mammalian cell cycle by the circadian clock: Modeling two coupled cellular rhythms. PLoS Comput Biol. 8(5):e1002516. doi:10.1371/journal.pcbi.1002516. PMID: 22693436.
- Gu X, Ma C, Yuan D, Song Y. 2012. Circulating soluble intercellular adhesion molecule-1 in lung cancer: A systematic review. Transl Lung Cancer Res. 1(1):36–44. doi:10.3978/j.issn.2218-6751.08.01. PMID: 25806153.
- Hoffman AE, Zheng T, Ba Y, Stevens RG, Yi CH, Leaderer D, Zhu Y. 2010. Phenotypic effects of the circadian gene Cryptochrome 2 on cancer-related pathways. BMC Cancer. 10:110. doi:10.1186/1471-2407-10-110. PMID: 20334671.
- Hoffman AE, Zheng T, Stevens RG, Ba Y, Zhang Y, Leaderer D, Yi C, Holford TR, Zhu Y. 2009. Clock-cancer connection in non-Hodgkin’s lymphoma: A genetic association study and pathway analysis of the circadian gene cryptochrome 2. Cancer Res. 69(8):3605–13. doi:10.1158/0008-5472.CAN-08-4572. PMID: 19318546.
- Hsu CM, Lin SF, Lu CT, Lin PM, Yang MY. 2012. Altered expression of circadian clock genes in head and neck squamous cell carcinoma. Tumour Biol. 33(1):149–55. doi:10.1007/s13277-011-0258-2. PMID: 22081375.
- Huang B, Carloss H, Wyatt SW, Riley E. 2009. Hormone replacement therapy and survival in lung cancer in postmenopausal women in a rural population. Cancer. 115(18):4167–75. doi:10.1002/cncr.24475. PMID: 19526591.
- Huber AL, Papp SJ, Chan AB, Henriksson E, Jordan SD, Kriebs A, Nguyen M, Wallace M, Li Z, Metallo CM, others. 2016. CRY2 and FBXL3 cooperatively degrade c-MYC. Mol Cell. 64(4):774–89. doi:10.1016/j.molcel.2016.10.012. PMID: 27840026.
- Kazandjian D, Blumenthal GM, Yuan W, He K, Keegan P, Pazdur R. 2016. FDA approval of gefitinib for the treatment of patients with metastatic EGFR mutation-positive non-small cell lung cancer. Clin Cancer Res. 22(6):1307–12. doi:10.1158/1078-0432.CCR-15-2266. PMID: 26980062.
- Kelleher FC, Rao A, Maguire A. 2014. Circadian molecular clocks and cancer. Cancer Lett. 342(1):9–18. doi:10.1016/j.canlet.2013.09.040. PMID: 24099911.
- Kettner NM, Katchy CA, Fu L. 2014. Circadian gene variants in cancer. Ann Med. 46(4):208–20. doi:10.3109/07853890.2014.914808. PMID: 24901356.
- Langer CJ, Besse B, Gualberto A, Brambilla E, Soria JC. 2010. The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol. 28(36):5311–20. doi:10.1200/JCO.2010.28.8126. PMID: 21079145.
- Lee JH, Sancar A. 2011. Regulation of apoptosis by the circadian clock through NF-kappaB signaling. Proc Natl Acad Sci U S A. 108(29):12036–41. doi:10.1073/pnas.1108125108. PMID: 21690409.
- Mao Y, Fu A, Hoffman AE, Jacobs DI, Jin M, Chen K, Zhu Y. 2015. The circadian gene CRY2 is associated with breast cancer aggressiveness possibly via epigenomic modifications. Tumour Biol. 36(5):3533–39. doi:10.1007/s13277-014-2989-3. PMID: 25740058.
- Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H. 2003. Control mechanism of the circadian clock for timing of cell division in vivo. Science. 302(5643):255–59. doi:10.1126/science.1086271. PMID: 12934012.
- Mullenders J, Fabius AW, Madiredjo M, Bernards R, Beijersbergen RL. 2009. A large scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathway. PLoS One. 4(3):e4798. doi:10.1371/journal.pone.0004798. PMID: 19277210.
- Ohta Y, Nozaki Z, Nozawa H, Kamesui T, Tsunezuka Y, Oda M, Watanabe G. 2001. The predictive value of vascular endothelial growth factor and nm23 for the diagnosis of occult metastasis in non-small cell lung cancer. Jpn J Cancer Res. 92(3):361–66. PMID: 11267948.
- Parent ME, El-Zein M, Rousseau MC, Pintos J, Siemiatycki J. 2012. Night work and the risk of cancer among men. Am J Epidemiol. 176(9):751–59. doi:10.1093/aje/kws318. PMID: 23035019.
- Pruitt SL, Laccetti AL, Xuan L, Halm EA, Gerber DE. 2017. Revisiting a longstanding clinical trial exclusion criterion: Impact of prior cancer in early-stage lung cancer. Br J Cancer. 116(6):717–25. doi:10.1038/bjc.2017.27. PMID: 28196065.
- Tokunaga H, Takebayashi Y, Utsunomiya H, Akahira J, Higashimoto M, Mashiko M, Ito K, Niikura H, Takenoshita S, Yaegashi N. 2008. Clinicopathological significance of circadian rhythm-related gene expression levels in patients with epithelial ovarian cancer. Acta Obstet Gynecol Scand. 87(10):1060–70. doi:10.1080/00016340802348286. PMID: 18720043.
- Unsal-Kacmaz K, Mullen TE, Kaufmann WK, Sancar A. 2005. Coupling of human circadian and cell cycles by the timeless protein. Mol Cell Biol. 25(8):3109–16. doi:10.1128/MCB.25.8.3109-3116.2005. PMID: 15798197.
- Yang SL, Ren QG, Wen L, Hu JL, Wang HY. 2017. Research progress on circadian clock genes in common abdominal malignant tumors. Oncol Lett. 14(5):5091–98. doi:10.3892/ol.2017.6856. PMID: 29113149.
- Yang SL, Yu C, Jiang JX, Liu LP, Fang X, Wu C. 2014. Hepatitis B virus X protein disrupts the balance of the expression of circadian rhythm genes in hepatocellular carcinoma. Oncol Lett. 8(6):2715–20. doi:10.3892/ol.2014.2570. PMID: 25360177.
- Yoshida K, Sato M, Hase T, Elshazley M, Yamashita R, Usami N, Taniguchi T, Yokoi K, Nakamura S, Kondo M, others. 2013. TIMELESS is overexpressed in lung cancer and its expression correlates with poor patient survival. Cancer Sci. 104(2):171–77. doi:10.1111/cas.12068. PMID: 23173913.
- Yuan P, Li J, Zhou F, Huang Q, Zhang J, Guo X, Lyu Z, Zhang H, Xing J. 2017. NPAS2 promotes cell survival of hepatocellular carcinoma by transactivating CDC25A. Cell Death Dis. 8(3):e2704. doi:10.1038/cddis.2017.131. PMID: 28333141.
- Zhang Z, Ma J, Li N, Sun N, Wang C. 2006. Expression of nuclear factor-kappaB and its clinical significance in nonsmall-cell lung cancer. Ann Thorac Surg. 82(1):243–48. doi:10.1016/j.athoracsur.2006.01.049. PMID: 16798222.
- Zhu Y, Rg S, Ae H, Lm F, Em K, Ea O, Davis S, Zheng T, Jl S. 2009. Testing the circadian gene hypothesis in prostate cancer: A population-based case-control study. Cancer Res. 69(24):9315–22. doi:10.1158/0008-5472.CAN-09-0648. PMID: 19934327.
- Zl Z, Mw W, Sun J, Yl S, Yc C, Yj H, Lj X. 2010. Effects of the biological clock gene Bmal1 on tumour growth and anti-cancer drug activity. J Biochem. 148(3):319–26. doi:10.1093/jb/mvq069. PMID: 20576619.